# CAP-IT Center for LNP RNA Immunoprevention

> **NIH NIH U54** · WEILL MEDICAL COLL OF CORNELL UNIV · 2022 · $1,180,595

## Abstract

Overall Component: Project Summary/Abstract
The overall goal of CAP-IT Center for RNA Immunoprevention (CRI) is to pre-clinically delineate, formulate and
validate liponanoparticle RNA (LNP RNA) vaccines for precision prevention of individuals with increased cancer
risk. The PI is Dr. Lipkin, an established leader in Cancer Prevention who has made several important, clinically
translated contributions to the field. Project 1 will develop and validate an LNP RNA immunoprevention vaccine
for Lynch syndrome, a genetic cancer predisposition syndrome with highly immunogenic recurrent neoantigens
shared among cancers from different patients. Project 2 will develop and validate an LNP RNA immune
interception vaccine for patients with lung non-solid nodule (NSN) pre-malignant neoplasms, a lung
adenocarcinoma precursor lesion. To achieve these goals, we will use state-of-the-art technologies, including
LNP RNA vaccine formulation, computational genomic tumor immunology, spatial genomics and
immunopeptidomics. To ensure CRI's scientific rigor and excellence, we have assembled a scientifically
outstanding CRI External Advisory Board (EAB), which includes 2021 Lasker Award winner Drew Weissman
(Penn) for his work on LNP RNA COVID19 vaccines. Overall, the CAP-IT CRI will develop state-of-the-art LNP RNA
immunoprevention and immune interception vaccines and provide a technologically powerful platform to
jumpstart additional CAP-IT CRI LNP RNA vaccine projects. We anticipate that CAP-IT CRI will propel both
Lynch syndrome and lung NSN vaccines to NCI PREVENT and CP-NET clinical trials within the next 5 years
and FDA approval/clinical translation within ten years.

## Key facts

- **NIH application ID:** 10505675
- **Project number:** 1U54CA272688-01
- **Recipient organization:** WEILL MEDICAL COLL OF CORNELL UNIV
- **Principal Investigator:** NASSER Khaled ALTORKI
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,180,595
- **Award type:** 1
- **Project period:** 2022-09-01 → 2027-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10505675

## Citation

> US National Institutes of Health, RePORTER application 10505675, CAP-IT Center for LNP RNA Immunoprevention (1U54CA272688-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10505675. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*